Lawrence Elmer, MD
Neurology · Toledo, OHNPI 1043206196
Payments from drug & device makers
Across 770 payments — averaging $1972.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sage Therapeutics, LLC$385K
- Neurocrine Biosciences, Inc.$264K
- Acadia Pharmaceuticals Inc$209K
- Teva Pharmaceuticals USA, Inc.$155K
- Amneal Pharmaceuticals LLC$130K
- AbbVie$97K
- plus $279K from 18 others
What the payments were for
- Consulting fees$121,87418%
- Speaking & faculty fees$505,09674%
- Travel & lodging$37,5215%
- Food & beverage$21,4243%
- Education$8690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sage Therapeutics, LLC | 8 | $384,850 |
| Neurocrine Biosciences, Inc. | 180 | $263,590 |
| Acadia Pharmaceuticals Inc | 215 | $209,372 |
| Teva Pharmaceuticals USA, Inc. | 110 | $154,714 |
| Amneal Pharmaceuticals LLC | 62 | $130,070 |
| AbbVie | 47 | $96,925 |
| Kyowa Kirin, Inc. | 53 | $88,555 |
| Sunovion Pharmaceuticals Inc. | 22 | $79,547 |
| UCB SA | 1 | $67,804 |
| Acorda Therapeutics, Inc | 22 | $22,080 |
| H. Lundbeck A S | 6 | $13,365 |
| MDD US Operations, LLC | 11 | $5,743 |
| Medtronic | 9 | $1,061 |
| UCB, Inc. | 10 | $930 |
| Pyros Pharmaceuticals, Inc. | 1 | $43 |
| AstraZeneca | 3 | $42 |
| Pfizer | 2 | $35 |
| Novartis | 2 | $25 |
| Saol Therapeutics Inc. | 1 | $17 |
| SK Life Science, Inc. | 1 | $16 |
| Aquestive Therapeutics, Inc. | 1 | $15 |
| Adamas Pharmaceuticals, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Neurelis, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$172,529
- INGREZZA$151,518
- AUSTEDO$96,057
- NOURIANZ$88,150
- Austedo XR$57,113
- RYTARY$36,721
- ONGENTYS$35,184
- INBRIJA$21,638
- CREXONT$5,910
- KYNMOBI$2,500
- Percept$707
- PERCEPT PC BRAINSENSE$129
- LONHALA MAGNAIR$120
- VYALEV$105
How this compares
$1,518,839 in reported general payments places this provider in the 95th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 144 | $679,812 |
| AustedoDeutetrabenazine | 71 | $504,950 |
| RytaryCarbidopa/Levodopa | 81 | $89,217 |
| Rasagiline Mesylate | 200 | $52,385 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 358 | $29,329 |
| NourianzIstradefylline | 14 | $25,589 |
| OngentysOpicapone | 18 | $24,612 |
| ExelonRivastigmine | 16 | $16,697 |
| Rivastigmine | 58 | $12,142 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 334 | $11,011 |
| Ropinirole ErRopinirole Hcl | 54 | $7,860 |
| AmantadineAmantadine Hcl | 103 | $6,813 |
| Rimantadine Hcl | 15 | $3,033 |
| Entacapone | 11 | $2,833 |
| Clonazepam | 178 | $2,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $209,372 | $679,812144 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $154,714 | $504,95071 claims |
| Amneal Pharmaceuticals LLCRytary | $130,070 | $89,21781 claims |
| Kyowa Kirin, Inc.Nourianz | $88,555 | $25,58914 claims |
| Neurocrine Biosciences, Inc.Ongentys | $263,590 | $24,61218 claims |
| NovartisExelon | $25 | $16,69716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 702 neurology providers in Ohio.
Other neurology in Toledo
- Mouhammad JumaaToledo$1.1M
- Howard SchechtToledo$564K
- Joel VandersluisDayton$12.3M
- Jerry MendellColumbus$11.5M
- Lawrence GoldstickDayton$6.9M
- Douglas ScharreColumbus$6.8M
- Robert BermelCleveland$6.4M
- Aaron BosterColumbus$6.3M
- Ryan DrakeCanton$5.5M
- Aram ZabetiCincinnati$5.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.